Bioorthogonal chemistry has provided an elaborate arsenal to manipulate native biological
processes in living systems. As the great advancement of nanotechnology in recent years …

Targeted protein degradation (TPD) has emerged as a revolutionary paradigm in drug
discovery and development, offering a promising avenue to tackle challenging therapeutic …

Targeted protein degradation (TPD) has emerged as an effective therapeutic strategy for a
wide range of diseases; however, the blood-brain barrier (BBB) limits access of degraders …

Targeted protein degradation technology has gained substantial momentum over the past
two decades as a revolutionary strategy for eliminating pathogenic proteins that are …

Aberrant aggregates of amyloid‐β (Aβ) and tau protein (tau), called amyloid, are related to
the etiology of Alzheimer disease (AD). Reducing amyloid levels in AD patients is a …

The redox-active metal ions, especially Cu2+, are highly correlated to Alzheimer's disease
(AD) by causing metal ion-mediated oxidative stress and toxic metal-bound β-amyloid (Aβ) …

In a recent Chem article, Liu et al. 1 introduced polydopamine-based lysosome-targeting
chimeras (KPLYs). In in vitro cellular models, KPLYs adeptly cross the blood-brain barrier to …

T cell-mediated immunity plays a pivotal role in cancer immunotherapy. The anticancer
actions of T cells are coordinated by a sequence of biological processes, including the …

Recent advancements in Alzheimer's disease (AD) research have led to the approval of
lecanemab and donanemab, highlighting the effectiveness of amyloid-beta (Aβ) degradation …

Targeted protein degradation (TPD) has revolutionized drug discovery by selectively
eliminating specific proteins within and outside the cellular context. Over the past two …